Sharechat Logo

Promisia names Rene de Wit as CEO, poised to launch pill for dogs with sore joints

Thursday 28th September 2017

Text too small?

Promisia Integrative, which makes a dietary supplement for sore joints, announced it has appointed Rene de Wit as its new chief executive and said it is on the verge of launching its new product to treat osteoarthritis in dogs. 

De Wit will take up the position on Oct. 9, replacing director Tom Brankin who has been acting managing director for the past six months.  De Wit has experience in fast-moving consumer goods, food manufacturing, printing, packaging, import/export, financial services and logistics, Promisia said in a release to the NZX. His former roles include CEO or general manager positions with Watson & Son, Colorite Group, and Scalzo Food Industries. 

The company's flagship product is Arthrem, a dietary supplement for joint support for humans. The proprietary extract made from the medicine herb Artemisia annua was originally tested as a malaria treatment in Papua New Guinea. It is grown for Promisia on a farm in Tanzania.

Brankin told BusinessDesk that the company is poised to launch its new product for dogs. Artevite will be sold through veterinary clinics, pet stores and online. The company has signed a marketing and distribution agreement with Brooklands Pet Products of New Plymouth which has an extensive countrywide marketing and distribution network.  Brankin said the product is currently being packaged and should be at Brooklands next week. 

In late August the company said sales in the six months to June 30 were $1.3 million, up 33 percent on the year, while the operating loss was slightly narrower at $349,000 versus a loss of $355,000 in the same period a year earlier.

The shares were up 3.6 percent at 2.9 cents and have fallen 8.9 percent over the past 12 months. 

(BusinessDesk)

Bond Offer: Infratil Ltd, 7.2 year & 10.2 year unsecured unsubordinated bond


  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

Goodman opts for underwritten $150m placement to raise capital
NZ dollar opens higher as dairy prices lift, oil eases
Napster's Sean Parker yet to seek OIO approval for Weta Digital stake
18th September 2019 Morning Report
Dairy product prices advance, bolstered by milk powders
MARKET CLOSE: NZ shares gain: F&P Healthcare rallies on big volume, Synlait extends gain
NZ dollar mixed after RBA says its ready to cut rate if necessary
OMV granted marine discharge consent for Great South Basin
More detail needed on migrant worker policy, big employer says
Briscoe Group says outlook uncertain

IRG See IRG research reports